Features Partner Sites Information LinkXpress
Sign In
Demo Company

NMR Spectroscopy Nature Bank Creates Limitless Opportunities for Drug Discovery

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Print article
Australian researchers have developed a new tool for finding natural compounds that could form the foundation of innovative therapeutic agents. 

The corresponding author, Prof. Ronald Quinn AM from Griffith University’s Eskitis Institute for Drug Discovery (Brisbane, Australia), reported that testing the new process on a marine sponge had delivered not only validation that the system is successful, but also a potential lead in the fight against Parkinson’s disease. “We have found a new screening method which allows us to identify novel molecules drawn from nature to test for biological activity,” Prof. Quinn said. “As it happens, the first new compound we discovered through this process has demonstrated a response in Parkinson’s disease cells.” 

The findings were published online April 15, 2014, in the chemistry journal Angewandte Chemie. The first author Dr. Tanja Grkovic said the screening process involves nuclear magnetic resonance (NMR) spectroscopy; a highly sensitive instrument through which it is possible to see natural products weighing as little as 20 micrograms. “When you are searching for nature-derived molecules, the jackpot is finding something that nobody has ever seen before and rather than just a variation on a known theme,” Dr. Grkovic said. “We began the project by selecting 20 marine sponge samples randomly from Griffith’s Nature Bank facility and using the NMR technique trying to visualize all the small molecules which could meet the requirements for a potential new drug. “The idea was to look at patterns of data and identify unusual or unique sets. We followed one such pattern and isolated a natural product with a novel skeleton which has turned out to be a molecule which was completely unknown previously.” 

Griffith’s Nature Bank is a novel drug discovery resource based on natural products found in China, Australia, and Papua New Guinea. It comprises more than 45,000 samples of plants and marine invertebrates, 200,000 semipurified fractions, 3,250 pure compounds and over 600 naturally occurring fragments. 

This NMR screening process provides a new way of searching all those natural samples stored in Nature Bank and uncovering the potential biological activity of the compounds within them. 

Deputy director of the Eskitis Institute and coauthor of the paper, Assoc. Prof. George Mellick, is a specialist researcher in neurodegenerative diseases such as Parkinson’s disease. He is excitied by the research prospects this new molecule may provide. “What is very intriguing about this novel natural product is that, while we have found it has an effect on cells sourced from a Parkinson’s patient, it showed a different biological activity on cells from healthy individuals,” Assoc. Prof. Mellick said. “This provides us with a new tool to study the fundamental biology of Parkinson's and to get a better understanding of the cellular processes involved in the development of this disease.” 

The Parkinson’s response is only the beginning, according to the scientists. “This new research technique opens the door to unlimited opportunities, both in terms of chemistry and biology research at Eskitis, as we continue the search for new therapies against disease,” Prof. Quinn said.

Related Links:

Griffith University’s Eskitis Institute for Drug Discovery

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.